16% of biotech stocks now trade below their cash value

Smart money is accumulating while retail investors flee...

Hey there,

Something bizarre is happening in biotech right now.

While revolutionary gene therapies are getting FDA approval and breakthrough treatments are reaching market, 16% of biotech companies are trading below their actual cash reserves. Access full story here.

-Christopher

P.S. Institutional investors are quietly buying at these levels for a specific reason. You really need to read this before it's too late.